Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.
| Website | http://aboleris-pharma.com |
| Employees | 13 (7 on RocketReach) |
| Founded | 2019 |
| Technologies |
JavaScript
,
HTML
,
PHP
+9 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Immune System, Immunotherapy, Clinical Stage, T Cell Therapy, Therapeutic Approaches, Novel Therapeutics, Drug Discovery, Drug Development, Biopharma, Pharmaceutical Research, Clinical Trials, Precision Medicine, Biotechnology, Immunomodulation, Translational Research, Pharmaceutical, Therapeutics |
| Competitors | Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, Sanofi, GSK, AstraZeneca, Bristol Myers Squibb, Gilead Sciences +45 more (view full list) |
Looking for a particular AbolerIS Pharma employee's phone or email?
AbolerIS Pharma Questions
Philippe Alen is the Chief Business Officer (fractional) of AbolerIS Pharma.
7 people are employed at AbolerIS Pharma.
Top AbolerIS Pharma Employees
-
25+
-
Ken Tignol
Head of Finance at AbolerIS Pharma
Antwerp, BE21 -
45+
-
Carole Guillonneau
Head of Research at AbolerIS Pharma
Pays de la Loire, France41 -
3
-
2
Related Companies
G2Crowd Trusted
300K+
Plugin Users
